Takeda Pharmaceutical Company
Search results
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world.
Daiichi Sankyo Company, Limited (Japanese: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. [3] . The company owns the American pharmaceutical company American Regent.
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in 29 countries/regions around the world. With more than 120 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
Jul 31, 2024 · Daiichi Sankyo is an innovative global healthcare company based in Japan underpinned by its Purpose: “To contribute to the enrichment of quality of life around the world”.
3 days ago · Drugmaker Daiichi Sankyo is working to boost production of its newer-generation cancer therapies that target diseased cells, across Japan, Europe and the US.
Learn More. Corporate Video. For people affected by cancer, Daiichi Sankyo turns hope into possibility. Possibility into reality. Our collective craft is medicine. We’re transforming how cancer and other disease are treated. More than 120 year of heritage inspires us to meet new challenges. Biomarker Testing and the Power of Information.
3 days ago · Drugmaker Daiichi Sankyo is working to boost production of its newer-generation cancer therapies that target diseased cells, across Japan, Europe and the United States.
Oct 19, 2023 · TOKYO, Oct 19 (Reuters) - Drugmaker Merck (MRK.N) will pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs, they said, in a deal that could be worth up to...
Oct 19, 2023 · Daiichi Sankyo will be solely responsible for manufacturing and supply. All three potentially first-in-class DXd ADCs are in various stages of clinical development for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments.
May 21, 2024 · BASKING RIDGE, N.J., May 21, 2024 -- (BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 45 abstracts in multiple cancers...
